Awesome.
After 6 weeks (day 43) treatment with PD1-Vaxx, one patient’s tumor was non-measurable indicating a complete response (CR), with three patients showing stabilization of disease (SD) and a single patient progressing (PD). The status of two patients from cohort 1 (1 x SD, 1 x CR) were unchanged at day 85.
These are encouraging results in patients who have progressed after previous treatment with checkpoint inhibitors including Keytruda®, Opdivo® or Tecentriq®. Further results and scans are scheduled over the coming weeks. The clinical results indicate that PD1-Vaxx is showing early signs of an immune responses in patients, with antibodies to the target biomarker PD1 evident in validated assays.
Imugene MD & CEO Leslie Chong said “Phase 1 trials are generally designed to look for safety, tolerability and early response signals to determine the optimal dose for further development. I am encouraged that we are seeing positive signals at such an early stage of our PD1-Vaxx Phase I trial”.
- Forums
- ASX - By Stock
- IMU
- Ann: Final Highest Dose in Phase 1 Clinical Trial of PD-VAXX
Ann: Final Highest Dose in Phase 1 Clinical Trial of PD-VAXX, page-3
-
- There are more pages in this discussion • 263 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
|
|||||
Last
6.2¢ |
Change
0.003(5.08%) |
Mkt cap ! $455.6M |
Open | High | Low | Value | Volume |
5.8¢ | 6.5¢ | 5.7¢ | $1.751M | 28.44M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 660964 | 6.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.2¢ | 549788 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 320000 | 0.061 |
8 | 435316 | 0.060 |
2 | 165000 | 0.059 |
7 | 1686333 | 0.058 |
6 | 1100000 | 0.057 |
Price($) | Vol. | No. |
---|---|---|
0.064 | 100000 | 1 |
0.065 | 428308 | 6 |
0.066 | 1116000 | 5 |
0.067 | 1247888 | 2 |
0.068 | 3350000 | 5 |
Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online